Jim Looman

582 total citations
16 papers, 175 citations indexed

About

Jim Looman is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jim Looman has authored 16 papers receiving a total of 175 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Jim Looman's work include Glioma Diagnosis and Treatment (9 papers), Lung Cancer Treatments and Mutations (5 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). Jim Looman is often cited by papers focused on Glioma Diagnosis and Treatment (9 papers), Lung Cancer Treatments and Mutations (5 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). Jim Looman collaborates with scholars based in United States, Netherlands and Italy. Jim Looman's co-authors include Shun Lü, Martin J. van den Bent, Peter Ansell, Christine K. Ratajczak, Annemiek Walenkamp, Earle Bain, Marica Eoli, Pim J. French, D. Ross Camidge and Hidehito Horinouchi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Jim Looman

14 papers receiving 169 citations

Peers

Countries citing papers authored by Jim Looman

Since Specialization

Citations

This map shows the geographic impact of Jim Looman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim Looman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim Looman more than expected).

Fields of papers citing papers by Jim Looman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jim Looman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim Looman. The network helps show where Jim Looman may publish in the future.

Co-authorship network of co-authors of Jim Looman

This figure shows the co-authorship network connecting the top 25 collaborators of Jim Looman. A scholar is included among the top collaborators of Jim Looman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jim Looman. Jim Looman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	OA16.03 Telisotuzumab Vedotin in Asian Patients with C-Met Protein-Overexpressing Non-Squamous EGFR WT NSCLC: Results from LUMINOSITY 2024 ·Journal of Thoracic Oncology ·(unknown), Jen‐Yu Hung, Zhenyu Ding, Se‐Hoon Lee, (unknown), Jim Looman, (unknown), (unknown), (unknown), Shuyue Xia, (unknown)	0
2	Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial. 2024 ·Journal of Clinical Oncology ·David Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Tudor–Eliade Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Ann Bradbury, Mor Moskovitz, (unknown), Pascale Tomasini, Alona Zer, Jim Looman, Christine K. Ratajczak, (unknown), Summer Xia, Shun Lü	8
3	Abstract CT214: Preliminary efficacy of telisotuzumab vedotin (Teliso-V) treatment in the 2L/3L setting in MET gene amplified (MET Amp), c-Met protein overexpressing (c-Met OE), non-squamous, non-small cell lung cancer (NSQ NSCLC): Retrospective analysis of LUMINOSITY 2023 ·Cancer Research ·D. Ross Camidge, Jonathan H. Goldman, (unknown), Peter Ansell, Summer Xia, (unknown), Jim Looman, Christine K. Ratajczak, (unknown), Shun Lü	5
4	Phase 2 study of telisotuzumab vedotin (Teliso-V) monotherapy in patients with previously untreated MET-amplified locally advanced/metastatic non-squamous non-small cell lung cancer (NSQ NSCLC). 2023 ·Journal of Clinical Oncology ·Hidehito Horinouchi, Yuji Shibata, Jim Looman, Yunxia Sui, (unknown), Shun Lü	6
5	Impact of genomic alterations measured in circulating tumor DNA (ctDNA) on clinical response to telisotuzumab vedotin treatment in patients with non-small cell lung cancer (NSCLC). 2023 ·Journal of Clinical Oncology ·D. Ross Camidge, Shobhit Baijal, Athanasios Vasilopoulos, Christine K. Ratajczak, Jim Looman, (unknown), Peter Ansell, Shun Lü	2
6	Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC). 2022 ·Journal of Clinical Oncology ·D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Penelope Ann Bradbury, Nathalie Daaboul, Pascale Tomasini, Tudor–Eliade Ciuleanu, David Planchard, Mor Moskovitz, Nicolas Girard, (unknown), Martin Dunbar, (unknown), Jim Looman, Christine K. Ratajczak, Shun Lü	61
7	Defining EGFR amplification status for clinical trial inclusion 2019 ·Neuro-Oncology ·Pim J. French, Marica Eoli, Juan Manuel Sepúlveda-Sánchez, Iris de Heer, Johan M. Kros, Annemiek Walenkamp, Jean‐Sébastien Frenel, Enrico Franceschi, Paul M. Clément, Michael Weller, Peter Ansell, Jim Looman, Earle Bain, Marie Morfouace, Thierry Gorlia, Martin J. van den Bent	28
8	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma 2019 ·Journal of Neuro-Oncology ·Andrew B. Lassman, Kenneth Aldape, Peter Ansell, Earle Bain, Walter J. Curran, Marica Eoli, Pim J. French, Manabu Kinoshita, Jim Looman, Minesh P. Mehta, Yoshihiro Muragaki, Yoshitaka Narita, Christopher Ocampo, Lisa Roberts-Rapp, (unknown), Michael A. Vogelbaum, Annemiek Walenkamp, Tony J. C. Wang, Peixin Zhang, Martin J. van den Bent	30
9	ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX–M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406 2018 ·Neuro-Oncology ·Martin J. van den Bent, Pim J. French, Marica Eoli, Juan Manuel Sepúlveda-Sánchez, Annemiek Walenkamp, (unknown), Enrico Franceschi, Paul M. Clément, Michael Weller, Iris de Heer, Jim Looman, Jyotirmoy Dey, Scott Krause, Hao Xiong, Peter Ansell, Sarah Nuyens, (unknown), (unknown), Thierry Gorlia, Vassilis Golfinopoulos	2
10	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406). 2018 ·Journal of Clinical Oncology ·Martin J. van den Bent, Pim J. French, Marica Eoli, Juan Manuel Sepúlveda-Sánchez, Anna Maria Elisabeth Walenkamp, Jean‐Sébastien Frenel, Enrico Franceschi, Paul M. Clément, Michael Weller, Iris de Heer, Jim Looman, Jyotirmoy Dey, Scott Krause, Hao Xiong, Peter Ansell, Sarah Nuyens, (unknown), (unknown), Thierry Gorlia, Vassilis Golfinopoulos	12
11	P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406) 2018 ·Neuro-Oncology ·Martin J. van den Bent, Pim J. French, Marica Eoli, (unknown), Annemiek Walenkamp, Michael Weller, Jim Looman, Peter Ansell, Thierry Gorlia, V. Golfinopoulos	3
12	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastoma 2017 ·Annals of Oncology ·Martin J. van den Bent, Lisa Roberts-Rapp, Peter Ansell, (unknown), Jim Looman, Earle Bain, Clara B. Ocampo, Kyle D. Holen, Erica Gomez, Andrew B. Lassman	1
13	ACTR-13. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION RATES OBSERVED IN SCREENING PATIENTS FOR RANDOMIZED CLINICAL TRIALS IN GLIOBLASTOMA 2017 ·Neuro-Oncology ·Martin J. van den Bent, Lisa Roberts-Rapp, Peter Ansell, James Lee, Jim Looman, Earle Bain, Christopher Ocampo, Kyle D. Holen, Erica Gomez, Andrew B. Lassman	1
14	QLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA 2017 ·Neuro-Oncology ·Paul M. Clément, Martin J. van den Bent, Marica Eoli, Juan Manuel Sepúlveda-Sánchez, Annemiek Walenkamp, Jean‐Sébastien Frenel, Enrico Franceschi, Michael Weller, Olivier Chinot, Filip De Vos, Nicolas Whenham, Paul Sanghera, Jim Looman, Ho‐Jin Lee, (unknown), Sarah Nuyens, (unknown), Thierry Gorlia, Corneel Coens, Vassilis Golfinopoulos	0
15	PDCT-02. EVALUATION OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN CHILDREN WITH HIGH GRADE GLIOMA (HGG) AND DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) 2017 ·Neuro-Oncology ·Martin J. van den Bent, Birgit Geoerger, Vassilis Golfinopoulos, Peter Ansell, Earle Bain, Jim Looman, Hao Xiong, (unknown), Kyle D. Holen, Darren Hargrave	1
16	Preliminary Experiences with HOE 498, a Novel Long-Acting Converting Enzyme Inhibitor, in Hypertensive Patients 1985 ·Journal of Cardiovascular Pharmacology ·Peter W. de Leeuw, (unknown), (unknown), Jim Looman, W. H. Birkenhäger	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact